Table 4 Summary of plasma remogliflozin etabonate, remogliflozin, and GSK279782 PK parameters in T2DM subjects a
Remogliflozin etabonate | Remogliflozin | GSK279782 | ||||
|---|---|---|---|---|---|---|
Remogliflozin etabonate dose | 50 mg | 500 mg | 50 mg | 500 mg | 50 mg | 500 mg |
AUC (0–∞) c (ng•h/mL) | ||||||
Geometric mean (CV%) | 8.91 (58) | 91.9 (46) b | 523 (38) | 5176 (44) | 130 (50) | 1293 (45) |
C max (ng/mL) | ||||||
Geometric mean (CV%) | 9.56 (39) | 83.9 (89) | 195 (46) | 1891 (49) | 34.6 (39) | 314 (39) |
T max (h) | ||||||
Median | 0.58 | 0.75 | 1.46 | 2.50 | 1.74 | 2.75 |
(range) | (0.33–0.78) | (0.33–2.50) | (0.33–2.00) | (0.33–4.00) | (0.75–4.00) | (0.75–4.00) |
T ½ (h) | ||||||
Geometric mean (CV%) | 0.61 (32) | 0.82 (69) b | 1.59 (27) | 3.93 (25) | 2.05 (24) | 3.28 (23) |
AUC (0–∞) ratio | ||||||
(Remogliflozin/remogliflozin etabonate) Geometric mean (CV%) | — | — | 59 (62) | 54 (38) | — | — |